Publications by authors named "Marco Testori"

Claim this Profile
C
Characterisation of the immunogenomic landscape of ovarian cancer uncovers a distinct subset of endometroid tumours associated with high CST2 expression and a favourable prognosis.
James Boyle, Jan Zaucha, Felicia Ng, Andreas Spitzmüller, Miljenka Vuko, Marco Testori

Cancer Res Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoring.
Julie Berthe, Pawan Poudel, Felix J Segerer, Emily C Jennings, Felicia Ng, Marco Testori

Front Immunol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of posterior indirect adhesive restorations (PIAR) with different preparations designs according to the adhesthetics classification.
Federico Ferraris, Tommaso Mascetti, Michele Tognini, Marco Testori, Alberto Colledani

Int J Esthet Dent· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies.
José Medina-Echeverz, Maria Hinterberger, Marco Testori, Marlene Geiger, Raphael Giessel

Nat Commun· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
Justin G Julander, Marco Testori, Cédric Cheminay, Ariane Volkmann

Front Immunol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NLRC4 Inflammasome-Driven Immunogenicity of a Recombinant MVA Mucosal Vaccine Encoding Flagellin.
Stephanie L Sanos, Ronny Kassub, Marco Testori, Marlene Geiger, Juliane Pätzold

Front Immunol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics.
Franco Lori, Davide De Forni, Elly Katabira, Denis Baev, Renato Maserati, Marco Testori

PLoS One· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis